Recent Birmingham-led studies
- PEPS2 – a potentially practice-changing study, led by Professor Gary Middleton, which has demonstrated the benefits of using the anti PD-L1 agent pembrolizumab in Performance Status 2 NSCLC patients.
- ANICCA-Class II - led by Professor Gary Middleton, this single arm Phase II study assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer, seeking to introduce a new immunotherapeutic stratifier.
GOTHAM (Clinical Trials Register): a phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in Haemophagocytic lymphohistiocytosis (HLH) or Macrophage activation syndrome (MAS) or relapsed/refractory solid tumours. Led by CI Dr Francis Mussai, it translates research into Myeloid Derived Suppressor Cell (MDSC) biology by Dr Mussai, Professor Gary Middleton and Dr Carmela De Santo. GOTHAM is being delivered across the ECMC adult and paediatric network.
- MATINS: a phase I/II study assessing Repeated Doses of CLEVER-1 Antibody FP-1305 in patients with advanced solid tumours. This novel commercial study is examining whether inhibiting Clever-1 is key to increasing patient responsiveness to cancer immunotherapy. It translates laboratory work by Birmingham CRUK Advanced Clinical Scientist Dr Shishir Shetty.